Package Leaflet: Information for the User
Prasugrel Vivanta 5 mg film-coated tablets EFG
prasugrel
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
The active substance is prasugrel, which belongs to a group of medicines called antiplatelet agents. Platelets are very small cells that circulate in the blood. When a blood vessel is damaged, for example cut, platelets clump together to help form a blood clot. Therefore, platelets are essential to help stop bleeding. The formation of clots in hardened blood vessels, such as arteries, can be very dangerous because they prevent blood from flowing, causing a heart attack (myocardial infarction), stroke, or death. Clots in arteries that supply blood to the heart can also reduce blood flow, causing unstable angina (severe chest pain).
Prasugrel inhibits platelet clumping, which reduces the chance of forming blood clots.
You have been prescribed prasugrel because you have had a heart attack or unstable angina and have been treated with a procedure to open up blocked heart arteries. You may have had one or more stents placed in the blocked or narrowed artery to restore blood flow to the heart. Prasugrel reduces the chance of having another heart attack or stroke, or of dying from one of these events. Your doctor will also prescribe acetylsalicylic acid (e.g., aspirin), another antiplatelet agent.
Do not take Prasugrel Vivanta
Warnings and precautions
Consult your doctor before starting to take prasugrel.
Consult your doctor or pharmacist before starting to take prasugrel if you are in any of the following situations:
You should contact your doctor immediately if you develop a condition called Thrombotic Thrombocytopenic Purpura (TTP). TTP is associated with fever and bruising (hematomas) under the skin that appear as localized red spots, with or without unexplained extreme fatigue, confusion, yellowing of the skin or eyes (jaundice) (see section 4 "Possible side effects").
Children and adolescents
Prasugrel should not be used in children or adolescents under 18 years of age.
Other medicines and Prasugrel Vivanta
Tell your doctor if you are taking, have recently taken, or might take any other medicines, including those obtained without a prescription, dietary supplements, and herbal products.
It is especially important that you inform your doctor if you are being treated with:
If these medications are administered with prasugrel, they may increase the risk of bleeding.
Tell your doctor if you are taking morphine or other opioids (used to treat acute pain).
Use other medications while taking prasugrel only if your doctor tells you to.
Pregnancy and breastfeeding
Tell your doctor if you become pregnant or are trying to become pregnant while taking prasugrel. You should take prasugrel only after talking to your doctor about the potential benefits and any potential risk to the fetus.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Driving and using machines
It is unlikely that prasugrel will affect your ability to drive or use machines.
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Follow the instructions for administration of this medicine exactly as indicated by your doctor. If you are unsure, consult your doctor or pharmacist again.
The usual dose of prasugrel is 10 mg per day. Your treatment will start with a single dose of 60 mg. If your weight is less than 60 kg or you are over 75 years old, the dose is 5 mg of prasugrel per day. Your doctor will also advise you to take acetylsalicylic acid and the exact dose you should take (usually between 75 mg and 325 mg per day).
You can take prasugrel with or without food. Take your dose every day at approximately the same time. Do not break or split the tablet.
It is important that you inform your doctor, dentist, and pharmacist that you are taking prasugrel.
If you take more Prasugrel Vivanta than you should
Contact your doctor or hospital directly as you may be at risk of excessive bleeding. You should show your doctor the packaging of prasugrel.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, telephone 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Prasugrel Vivanta
If you forget to take your scheduled daily dose, take prasugrel when you remember. If you forget to take your dose for a whole day, take your usual dose of prasugrel the next day. Do not take a double dose to make up for forgotten doses.
If you stop taking Prasugrel Vivanta
Do not stop your treatment without consulting your doctor. If you stop taking prasugrel too soon, the risk of having a heart attack may increase.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Contact your doctor immediatelyif you experience any of the following signs:
All of these can be signs of a stroke. A stroke is a rare side effect of prasugrel in patients who have never had a stroke or a transient ischemic attack.
You should also contact your doctor immediatelyif you notice any of the following signs:
Tell your doctor promptlyif you experience any of the following signs:
All of these can be signs of bleeding, the most common side effect with prasugrel. Although rare, severe bleeding can be life-threatening.
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Spanish Medicines and Healthcare Products Agency (AEMPS) through the website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Store below 25°C.
Do not use this medicine after the expiry date which is stated on the packaging after EXP. The expiry date is the last day of the month shown.
Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to a pharmacy for disposal. This will help protect the environment.
Prasugrel Vivanta 5 mg: Each tablet contains 5.490 mg of prasugrel hydrochloride, equivalent to 5 mg of prasugrel.
Core of the tablet: microcrystalline cellulose, mannitol (E421), sodium croscarmellose, hypromellose (E464), magnesium stearate.
Coating of the tablet: lactose monohydrate, HPMC 2910 / hypromellose, titanium dioxide (E171), triacetin (E1518), yellow iron oxide (E172), and talc.
Prasugrel Vivanta 5 mg: Yellow, oval, biconvex film-coated tablets with "5" engraved on one side and "M" on the other.
Prasugrel Vivanta is available in aluminum blisters in packs of 14, 28, 30, 30 (x1), 56, 84, 90 (x1), and 98 tablets.
Not all pack sizes may be marketed.
Marketing authorization holder:
Vivanta Generics s.r.o.
Trtinová 260/1, Cakovice
196 00 Prague 9
Czech Republic
Manufacturer:
Pharmadox Healthcare Limited,
KW20A Kordin Industrial Park
Paola, PLA3000
Malta
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Local Representative:
Mabo-Farma S.A.
Calle Vía de los Poblados 3, Edificio 6
28033 Madrid
Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Netherlands Prasugrel Vivanta 5 mg film-coated tablets
Germany Prasugrel Vivanta 5 mg film-coated tablets
Spain Prasugrel Vivanta 5 mg film-coated tablets EFG
Portugal Prasugrel Vivanta
Date of last revision of this leaflet: July 2023
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/.